Enhancing the antitumor effect of methotrexate in intro and in vivo by a novel targeted single-walled carbon nanohorn-based drug delivery system

RSC Advances ◽  
2016 ◽  
Vol 6 (53) ◽  
pp. 47272-47280 ◽  
Author(s):  
Ran Wang ◽  
Hongjing Cui ◽  
Junling Wang ◽  
Nannan Li ◽  
Qian Zhao ◽  
...  

The present research reports a smart multifunctional oxidized single-wall carbon nanohorns (oxSWNHs) drug delivery system (DDS) which could enhance the anti-tumor effect of methotrexate (MTX).

2014 ◽  
Vol 2 (29) ◽  
pp. 4726-4732 ◽  
Author(s):  
Daiqin Chen ◽  
Chao Wang ◽  
Feng Jiang ◽  
Zhuang Liu ◽  
Chunying Shu ◽  
...  

Single-walled carbon nanohorns (SWNHs) have exhibited many special advantages in biomedical applications.


2016 ◽  
Vol 4 (3) ◽  
pp. 529-538 ◽  
Author(s):  
Lin Dai ◽  
Kefeng Liu ◽  
Chuanling Si ◽  
Luying Wang ◽  
Jing Liu ◽  
...  

Ginsenoside Rb1 is shown to self-assemble with anticancer drugs to form stable nanoparticles, which have greater anticancer effectsin vitroandin vivothan the free drugs.


2013 ◽  
Vol 16 (1) ◽  
pp. 40 ◽  
Author(s):  
Chengqun Chen ◽  
Huijuan Zhang ◽  
Lin Hou ◽  
Jinjin Shi ◽  
Lei Wang ◽  
...  

Purpose. The aim of this study was to prepare a new neovascularity targeting antitumor drug delivery system mediated by single-walled carbon nanotubes (SWNTs). Methods. In this study, antiangiogenesis agent 2-methoxyestradiol was loaded by SWNTs via π~π accumulation. The SWNTs were then linked with NGR (Asn-Gly-Arg) peptide, which could target tumor angiogenesis. This drug delivery system was characterized by transmission electron microscope, scanning electron microscopy, and atomic force microscope analysis. The suppression efficacy of tumor growth in cultured breast cancer cell line was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The in vivo antitumor activity was evaluated on the Sarcoma (S180) tumor-bearing mice model. Results. The characteristics of this drug delivery system showed that the particle of complex was 190 ± 4.3 nm in size distribution and 23.56 ± 2.03 mV in zeta potential. The inhibition ratio of this SWNTs drug delivery system at 24, 48, and 72 h was about 57.7%, 83.6%, and 88.2%. Compared with normal saline group, the relative tumor volumes in the 2ME, SWNTs-2ME, and NGR-SWNTs-2ME groups were decreased 1 week after administration. Conclusion. This novel neovascularity targeting drug delivery system containing NGR-SWNTs-2ME may be beneficial to improve treatment efficacy and minimize side effects in future cancer therapy. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.


2020 ◽  
Vol Volume 14 ◽  
pp. 4343-4362
Author(s):  
Rehab Abdelmonem ◽  
Marian Sobhy Azer ◽  
Amna Makky ◽  
Abdelazim Zaghloul ◽  
Mohamed El-Nabarawi ◽  
...  

RSC Advances ◽  
2016 ◽  
Vol 6 (95) ◽  
pp. 93147-93161 ◽  
Author(s):  
Afzal Hussain ◽  
Sandeep Kumar Singh ◽  
Neeru Singh ◽  
Priya Ranjan Prasad Verma

This study aimed to formulate a self-nanoemulsifying drug delivery system (SNEDDS) for enhanced pharmacokinetic (PK) behavior of rifampicin and isoniazid using excipients holding innate anti-mycobacterial activity followed within vivo–in silicopredictions using GastroPlus™.


RSC Advances ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. 6501-6510 ◽  
Author(s):  
Jie Liang ◽  
Xia Dong ◽  
Chang Wei ◽  
Deling Kong ◽  
Tianjun Liu ◽  
...  

A phthalocyanine incorporated alginate hydrogel with rhodamine was monitored by fluorescence imaging as a dual fluorescent drug delivery system.


Author(s):  
ShirishaG. Suddala ◽  
S. K. Sahoo ◽  
M. R. Yamsani

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.


2014 ◽  
Vol 10 (2) ◽  
pp. 263-270 ◽  
Author(s):  
Maulick Chopra ◽  
Usha Y. Nayak ◽  
Aravind Kumar Gurram ◽  
M. Sreenivasa Reddy ◽  
K.B. Koteshwara

Sign in / Sign up

Export Citation Format

Share Document